Shorla Pharma scores an expedited review for its mystery candidate to treat T-cell malignancies

Nicole DeFeudis

Editor

Since launching Shorla Pharma three years ago to design better versions of existing cancer drugs, co-founders Sharon Cunningham and Orlaith Ryan have offered scarce details …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Shorla Pharma scores an expedited review for its mystery candidate to treat T-cell malignancies

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Shorla Phar­ma scores an ex­pe­dit­ed re­view for its mys­tery can­di­date to treat T-cell ma­lig­nan­cies

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Shorla Pharma scores an expedited review for its mystery candidate to treat T-cell malignancies